The drug for treating erectile dysfunction :: Consumers survey results of for 2 quarter of 2012

Consumers survey results of for 2 quarter of 2012 in category

Gynecology, urology, nephrology / The drug for treating erectile dysfunction

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		Імпаза (Materia Medica – Ukraine)	50.00%	5

2.		Верона (Herbion)	20.00%	2

2.		Левитра (Bayer)	20.00%	2

4.	2	Йохімбекс-Гармонія (Борщагівський ХФЗ)	10.00%	1

4.	6	Пенімекс (Дж.Б.Кемикалз енд Фармасьютикал Лтд)	10.00%	1

4.		Потенін-флора (Медіфлора)	10.00%	1

4.	2	Сілагра (Cipla Ltd)	10.00%	1

–.	3	~~Новігра (Nabros Pharma)~~	~~10.00%~~	1

–.	5	Трібестан (Sopharma)	0.00%	0

–.	3	Йохімбін – Шпігель	0.00%	0

–.	4	Стаміна (Adjanta Pharma Limited)	0.00%	0

–.	5	Цефагіл (Cefak)	0.00%	0

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2012, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.